Alexion Pharmaceuticals’ recombinant human anti-ATTR-immunoglobulin G1 monoclonal antibody was granted FDA orphan designation as a treatment of transthyretin amyloidosis, according to a post to the agency’s website.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca price target raised to 12,900 GBp from 12,700 GBp at Morgan Stanley
- AstraZeneca call volume above normal and directionally bullish
- Microsoft upgraded, Nike downgraded: Wall Street’s top analyst calls
- AstraZeneca upgraded to Buy from Hold at Jefferies
- AstraZeneca says Dato-DXd showed significant improvement for primary endpoint